Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
5.13 USD | +214.72% | +214.72% | +230.97% |
Business Summary
Number of employees: 121
Sales per Business
USD in Million | 2022 | Weight | 2023 | Weight | Delta |
---|---|---|---|---|---|
Probody Therapeutics
100.0
%
| 53 | 100.0 % | 101 | 100.0 % | +90.38% |
Sales per region
USD in Million | 2022 | Weight | 2023 | Weight | Delta |
---|---|---|---|---|---|
United States
100.0
%
| 53 | 100.0 % | 101 | 100.0 % | +90.38% |
Managers
Managers | Title | Age | Since |
---|---|---|---|
Sean McCarthy
CEO | Chief Executive Officer | 57 | 01/10/01 |
Chris Ogden
DFI | Director of Finance/CFO | 40 | 02/21/02 |
Marcia Belvin
CTO | Chief Tech/Sci/R&D Officer | 57 | 01/18/01 |
Yu Waye Chu
CTO | Chief Tech/Sci/R&D Officer | 56 | 17/23/17 |
Lloyd Rowland
CMP | Compliance Officer | 67 | 01/18/01 |
Jeffrey Landau
PRN | Corporate Officer/Principal | 46 | 01/21/01 |
Hong He
PRN | Corporate Officer/Principal | 55 | 01/20/01 |
Danielle Olander
HRO | Human Resources Officer | - | 01/14/01 |
Members of the board
Members of the board | Title | Age | Since |
---|---|---|---|
James Meyers
BRD | Director/Board Member | 58 | 20/18/20 |
Elaine Jones
BRD | Director/Board Member | 69 | 01/14/01 |
Sean McCarthy
CEO | Chief Executive Officer | 57 | 01/10/01 |
Mani Mohindru
BRD | Director/Board Member | 52 | 16/20/16 |
Halley Gilbert
BRD | Director/Board Member | 54 | 27/20/27 |
Matthew Young
BRD | Director/Board Member | 54 | 01/15/01 |
Alan Ashworth
BRD | Director/Board Member | 63 | 29/21/29 |
Share class
Vote | Quantity | Free-Float | Company-owned shares | Total Float | |
---|---|---|---|---|---|
Stock A | 1 | 67,731,764 | 66,926,077 ( 98.81 %) | 0 | 98.81 % |
Company contact information
CytomX Therapeutics, Inc.
151 Oyster Point Boulevard Suite 400
94080-1913, South San Francisco
+650 515 3185
http://www.cytomx.comSector
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+230.97% | 347M | |
-1.17% | 104B | |
+2.87% | 97.47B | |
+4.51% | 22.25B | |
-14.77% | 21.68B | |
-8.91% | 18.2B | |
-39.98% | 17.02B | |
-13.21% | 16.36B | |
+8.55% | 14.39B | |
+35.75% | 12.37B |
- Stock Market
- Equities
- CTMX Stock
- Company CytomX Therapeutics, Inc.